Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Crossover Study to Assess the Comparative Pharmacokinetics, Bioequivalence, and Safety of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.

NCT07421011 is registered in ClinicalTrials.gov with Valenta Pharm JSC as lead sponsor.

NCT NCT07421011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07421011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Crossover Study to Assess the Comparative Pharmacokinetics, Bioequivalence, and Safety of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.
Lead sponsor
Valenta Pharm JSC
Phase
Phase 1
Overall status
Recruiting
Start date
November 6, 2025
Completion date
December 31, 2026
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biliary dyskinesia, gallstone disease, gerd, irritable bowel syndrome, postcholecystectomy syndrome